Seretide Dosage/Direction for Use

SERETIDE is for oral inhalation only.
Patients should be made aware that SERETIDE must be used regularly for optimum benefit, even when asymptomatic.
Patients should be regularly reassessed by a doctor, so that the strength of SERETIDE they are receiving remains optimal and is only changed on medical advice.
Asthma: The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.
If asthma is insufficiently controlled by monotherapy with inhaled corticosteroids, transfer to SERETIDE at therapeutically equivalent doses of the corticosteroid can lead to improved asthma control. For patients whose asthma is well controlled by inhaled corticosteroids, transfer to SERETIDE makes it possible to reduce the dose of corticosteroid while retaining the same asthma control.
Patients should be given the strength of SERETIDE containing the appropriate fluticasone propionate dosage for the severity of their disease.
Accuhaler: Where the control of symptoms is maintained with the lowest strength of the combination then the next step could include a test of inhaled corticosteroid alone. As an alternative, patients requiring a long acting beta-2-agonist could be titrated to SERETIDE given once daily if, in the opinion of the prescriber, it would be adequate to maintain disease control. In the event of once daily dosing, when the patient has a history of nocturnal symptoms the dose should be given at night and when the patient has a history of mainly day-time symptoms the dose should be given in the morning.
If an individual patient should require dosages outside the recommended regimen, appropriate doses of beta-agonist and/or corticosteroid should be prescribed.
Adults and adolescents 12 years and older: One inhalation (50 mcg salmeterol and 100 mcg fluticasone propionate) twice daily; or One inhalation (50 mcg salmeterol and 250 mcg fluticasone propionate) twice daily; or One inhalation (50 mcg salmeterol and 500 mcg fluticasone propionate) twice daily.
Children 4 to 11 years of age: One inhalation (50 mcg salmeterol and 100 mcg fluticasone propionate) twice daily.
There are no data available for use of SERETIDE in children aged under 4 years.
Inhaler: Adults and adolescents 12 years and older: Two inhalations of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily; or Two inhalations of 25 mcg salmeterol and 125 mcg fluticasone propionate twice daily; or Two inhalations of 25 mcg salmeterol and 250 mcg fluticasone propionate twice daily.
Children 4 years and older: Two inhalations of 25 mcg salmeterol and 50 mcg fluticasone propionate twice daily.
There are no data available for use of SERETIDE in children aged under 4 years.
Special patient groups: There is no need to adjust the dose in elderly patients or in those with renal or hepatic impairment.
Chronic Obstructive Pulmonary Disease (COPD): Accuhaler: Adults (18 years and older): One inhalation (50mcg salmeterol and 250mcg fluticasone propionate) twice daily; or One inhalation (50mcg salmeterol and 500mcg fluticasone propionate) twice daily.
Elderly and patients with impaired renal or hepatic function: There is no need to adjust the dose in the otherwise healthy elderly or in patients with impaired renal function. Since salmeterol is predominantly cleared by hepatic metabolism, patients with hepatic disease should be closely monitored.
Inhaler: Adults: Two inhalations of 25 mcg salmeterol and 250 mcg fluticasone propionate twice daily; or Two inhalations of 25 mcg salmeterol and 125 mcg fluticasone propionate twice daily may be a consideration in patients who are at greater risk of inhaled corticosteroid adverse effects.